iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023

Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan Health Care Conference, JPM Week, in January 2023.

iQure’s portfolio of treatments in Epilepsy, Pain and other neurodegenerative diseases has had a number of positive developments in the last few months. As a result, iQure Pharma has intensified its focus in the areas of strategic partnering and fundraising. Pawel Zolnierczyk, CEO and Henk de Wilde, COO and R&D Director, will participate in JPM Week to further explore strategic collaborations with pharma and expand current fundraising activities.

“These are exciting times for iQure with very promising market traction and significant interest from pharma for both of our assets,” said iQure CEO Pawel Zolnierczyk. “We are currently in active discussions with large pharma and look forward to continuing these at JPM. While we are there, we will be meeting with VCs and CVCs to expand our fundraising efforts.”

For those interested in meeting with iQure Pharma in San Francisco during JPM Week, please register here:

iQure Pharma at 2023 JPM BIO Partnering

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQ-007 shows no abuse potential in FDA recommended panel of tests

Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that iQ-007, a novel anticonvulsant and analgesic compound, showed no binding to targets in the drug abuse potential panel.

In line with the FDA guidance document, “Assessment of abuse potential of drugs” from January 2017, a full set of 44 potential targets were tested against a high dose of 100 uM of iQ-007 and no relevant binding was observed.

“This is very good news and an important step in the continued development of iQ-007 as a promising therapeutic,” said iQure Chief Operating Officer Henk de Wilde. “With so many drugs in the epilepsy and pain area showing abuse potential, it is comforting to know that iQ-007 shows no potential for abuse and truly is a non-opioid therapeutic.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma researchers seek non-opioid alternatives to manage neuropathic pain

3 November 2022 - In a newly published article in Health Tech World, Henk De Wilde, Chief Operating Officer and R&D Director, iQure Pharma Inc., discusses how better understanding of pain is helping researchers to develop novel therapeutics as non-opioid alternatives to manage neuropathic pain. Neuropathic pain is a severe form of chronic pain that's notoriously hard to treat primarily because of its complex pain biology.

iQure Pharma Inc.'s goal is to provide different approaches that can provide better therapeutics for neuropathic pain, to help the millions around the globe whose "excruciating pain is an inescapable reality of life."

Neuropathic pain patients make up an unwilling part of the opioid crisis, as nearly 60 percent of peripheral neuropathy patients end up taking opioids, often chronically.

Mayo Clinic researchers also reported in 2021, that more patients with newly diagnosed diabetic neuropathy were prescribed opioids during the years spanning 2014-2018 than were prescribed guideline-recommended medications.

Read the full text of the article here: http://ow.ly/KsJu50Lr2lk